{
    "code": 0,
    "data": [
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Monday February 02 2026 has been uploaded on the Companys website.",
            "news_id": "559a2b2c-60a6-4c21-8343-aa5add4ce7da",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e557fd6c-8af4-4ae2-9928-68d5f083c904.pdf",
            "news_date": "2026-02-04 15:16:51",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q3 FY 2025-26 Earnings Call held on 02nd February 2026 on the website of the Company.",
            "news_id": "801b3236-6fd1-4add-aefb-f783a58a5bbd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbc49df8-9d42-4521-b7be-1f74e8a53b1c.pdf",
            "news_date": "2026-02-02 13:38:05",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q3 FY 25-26",
            "news_id": "219d4b86-a7fd-4d04-bdec-7669e0cec21c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=856749e4-3647-45da-8001-1814468ab0bc.pdf",
            "news_date": "2026-01-30 20:20:09",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Earnings Call is attached",
            "news_id": "02ed6cd0-aa10-4482-b3cd-8ca02d6cfdd7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c995d72a-dd22-44a4-a163-01fcfee9a18e.pdf",
            "news_date": "2025-11-19 17:17:04",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q2 FY 2025-26 Earnings Call held on 17th November 2025 on the website of the Company",
            "news_id": "d07eaef4-a18e-4825-889a-274fc66bd732",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f588bf04-ebbe-402b-abcd-1b8e6aa897b4.pdf",
            "news_date": "2025-11-17 13:01:13",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q2 FY 25-26",
            "news_id": "bf943ffe-4845-464b-b214-d3f9a549bd84",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56fa1426-7a72-499d-8b43-3b4d1fad129f.pdf",
            "news_date": "2025-11-14 18:12:17",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q1 FY 25-26",
            "news_id": "e8e3b00b-9029-440f-8675-7b4cbc19d03b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6139070-f93f-4e0b-b520-cdcf5431009a.pdf",
            "news_date": "2025-08-14 18:21:34",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June 2025",
            "news_body": "Please find attached herewith Unaudited Financial Results for the first quarter ended 30th June 2025",
            "news_id": "477f84e9-7149-4cf0-b8ec-621db6f016d7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b72a6b85-71e4-4be2-a5d3-39c2effe26cd.pdf",
            "news_date": "2025-08-14 17:14:39",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2025",
            "news_body": "Audio recording of Investor Day 2025 held on 16th July 2025.",
            "news_id": "562de002-e0be-45e5-bf79-952d13159b70",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=740ed0cc-a602-497e-975f-1c66c12d2b1b.pdf",
            "news_date": "2025-07-23 16:11:42",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Day 2025 Presentation is enclosed for reference.",
            "news_id": "275e5357-cadf-446b-8cbd-fc153c3e37d8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5659eafc-f281-4f83-bbde-3c181a311e99.pdf",
            "news_date": "2025-07-16 16:31:20",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 19th May 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR) Regulations 2015 the transcript of the Earnings call held on Monday May 26 2025 for the fourth quarter ended March 31 2025 has been uploaded on the Companys website.",
            "news_id": "6f13ccef-def5-40a5-8dc2-e445cf8dc5ad",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8d7f8ed-6f40-476a-914a-2b00435fa31a.pdf",
            "news_date": "2025-05-27 18:12:59",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of Q4 FY 2024-25 earnings call held on 26th May 2025 on the website of the Company.",
            "news_id": "71900f70-ac43-4760-8458-813ad1a6f5be",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebf8a7bf-f74a-428a-a36d-85b0be147fff.pdf",
            "news_date": "2025-05-26 17:46:50",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q4 F.Y. 2024-25",
            "news_id": "0649b3f6-58b6-4cf1-a04c-21c5a3096734",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4caf64a2-3797-4495-8cea-68f00d80fc01.pdf",
            "news_date": "2025-05-23 21:24:01",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 5th February 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR) Regulations 2015 the transcript of the Earnings Call held on Monday 17th February 2025 for the third quarter ended December 31 2024 has been uploaded on the Companys website.",
            "news_id": "d16236a5-d30b-4d01-9571-8135d127cb8f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b9efbda-ee4a-4042-91ea-1698580069eb.pdf",
            "news_date": "2025-02-19 17:01:37",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q3 FY 24-25",
            "news_id": "66654668-262f-4b59-bee8-009031a569ca",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6dc274d1-2f3b-4867-afd7-26f68eed8911.pdf",
            "news_date": "2025-02-14 19:04:02",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of earnings call held on Monday, November 18, 2024 for the second quarter ended September 30, 2024 has been uploaded on Company''s website.",
            "news_id": "082b2214-c50c-45b3-b6fd-47a1f1414954",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a5cc6e3-bbc1-473a-9506-b5999588c822.pdf",
            "news_date": "2024-11-21 17:19:47",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q2 FY 2024 - 25 Earnings Call held on 18th November, 2024 on the website of the Company.",
            "news_id": "8eb1c80c-e75b-4cdc-91b0-2182b6e9966b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a696c3d7-be75-40a1-a8d5-a8131b4753e4.pdf",
            "news_date": "2024-11-18 15:57:24",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q2 FY 24-25",
            "news_id": "0aff3895-f0f5-4f1e-b916-5e58386e1bb3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85d2b081-3caf-4aef-b2dc-8d3e51336c19.pdf",
            "news_date": "2024-11-14 19:47:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of earnings call held on Friday, August 16, 2024 for the first quarter ended June 30, 2024 has been uploaded on Company''s website.",
            "news_id": "ba95694c-61eb-4667-aebd-b0a495917185",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e07f0ee2-79b8-419c-be62-6a5911f989ca.pdf",
            "news_date": "2024-08-20 15:39:39",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording for Q1 FY 2024-25 has been uploaded on Company''s website.",
            "news_id": "70d6c7c6-0474-49ec-bae2-ee6977452f67",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac617c07-2608-473b-8fac-6da9dfd020f3.pdf",
            "news_date": "2024-08-16 11:54:42",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q1 FY 24-25 attached.",
            "news_id": "856990b4-f5e3-44ee-953d-e55e1a3ee56b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b20d8d1f-1613-4f19-b8ce-8445e569d054.pdf",
            "news_date": "2024-08-14 18:50:56",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2024",
            "news_body": "Audio Recording of Investor Day 2024 held on 30th May, 2024",
            "news_id": "185814cf-0398-482e-a877-d41aec01dee8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=263b21b1-5361-4d4a-b408-436169f88361.pdf",
            "news_date": "2024-05-31 08:42:33",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Further to our communication dated 17th May, 2024, attached is the copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2024 which is scheduled today in Mumbai.",
            "news_id": "7eece272-5daa-42c7-a9ca-4cb1df175863",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f91f708-893b-4a3d-a8cf-ac4f2b99995a.pdf",
            "news_date": "2024-05-30 17:06:11",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on May 27, 2024 has been uploaded on the Company''s website.",
            "news_id": "f4a22628-bf69-42a8-a873-9e36fa9e84c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12c38fea-32b1-4125-a8d1-a580478385fe.pdf",
            "news_date": "2024-05-29 18:00:45",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 2023-24 Earnings call held on 27th May 2024, on the website of the Company",
            "news_id": "7c82434e-81c5-474c-9dce-cb4ffa92a6a3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f283cf7-82fe-4d69-885e-87210a76a5b2.pdf",
            "news_date": "2024-05-27 16:20:15",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q4 FY 23-24 and FY 23-24.",
            "news_id": "a51f15fc-9811-4384-895d-d641b9073a52",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fa7d259-23f1-478c-85bd-7eb246f1b35f.pdf",
            "news_date": "2024-05-24 23:26:40",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Friday, February 16, 2024 for the third quarter and nine months ended December 31, 2023 has been uploaded on the Company''s website.",
            "news_id": "5605e193-fdd1-455e-95de-c3b8786db99c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8af58f75-5319-4b22-ba23-4d25e7365312.pdf",
            "news_date": "2024-02-19 10:56:16",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 FY 2023-24 Earnings Call held on 16th February, 2024 on the website of the Company.",
            "news_id": "64ce99ac-bedd-4d34-a812-0143e749836d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea6ff388-ab16-4175-86ed-e1cf9abfbbd7.pdf",
            "news_date": "2024-02-16 12:58:15",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q3 FY23-24",
            "news_id": "547f2da5-99a8-44ac-8302-d67d4e4e4465",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1754436d-4da9-4ee0-9a44-b4dde158c324.pdf",
            "news_date": "2024-02-14 20:03:17",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2023",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2023.<BR> <BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 06:20 p.m.<BR> <BR> The copy of the said results and Limited Review Report of Auditors is enclosed herewith.<BR>  <BR> These are also being made available on the website of the Company",
            "news_id": "8c0896c1-1db3-48ef-a204-2b348849f381",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9664d8f2-05c6-4fb7-983f-1683b177590b.pdf",
            "news_date": "2024-02-14 18:44:51",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Wednesday, November 15, 2023 for the second quarter and half year ended September 30, 2023 has been uploaded on the Company''s website.",
            "news_id": "59f15b1e-d31c-4a54-a654-25d28a6353bc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ecd601e-4c1b-4b7d-a41a-bbf745608866.pdf",
            "news_date": "2023-11-20 16:18:05",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q2 FY 2023-24 Earnings Call held on 15th November, 2023 on the website of the Company.",
            "news_id": "da2dfbee-6286-4301-ace4-d7de25dcdaf6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f2b87942-95ad-4490-b101-4a250eb92610.pdf",
            "news_date": "2023-11-15 17:39:25",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation Q2 FY 23-24",
            "news_id": "44f9f578-60fd-4337-9808-a8a9abff557b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=475259ee-4bb0-453d-85ec-ed5402ee048e.pdf",
            "news_date": "2023-11-10 21:11:40",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September, 2023",
            "news_body": "Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2023. The said Board Meeting commenced at 02:00 p.m. and ended at 06:40 p.m. The copy of the said results and Limited Review Report of Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.",
            "news_id": "2692324e-d369-499e-98f2-8334f8198794",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd21a91c-2316-4e78-9509-cf52e9c498de.pdf",
            "news_date": "2023-11-10 18:57:41",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Glenmark Pharma announces proposed divestment of Majority Stake in Glenmark Life Sciences Limited",
            "news_id": "efdaea3e-9855-4810-814b-1baf4b61acc1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8382289-c246-4331-9ebf-53a00bbf84e6.pdf",
            "news_date": "2023-09-21 18:50:42",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the Earnings Call held on Monday, August 14, 2023 for the first quarter ended June 30, 2023 has been uploaded on the Company''s website.",
            "news_id": "145fde97-6d9c-4909-a879-7dbaa350fb6a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61f9a8c2-a531-4146-830f-3c03f60d3050.pdf",
            "news_date": "2023-08-21 16:59:50",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q1 FY 2023-24 Earnings Call held on 14th August, 2023 on the website of the Company.",
            "news_id": "da496389-803a-4e0a-9948-102ecfad1e6b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70c1fef9-f953-41ce-a0d0-3cc01dee6ee1.pdf",
            "news_date": "2023-08-14 17:01:58",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation - Q1 FY 23-24",
            "news_id": "7077160d-a922-48ad-add8-bac8eeacbb97",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae9f84c7-0698-4673-b390-7bd81e4cfd7e.pdf",
            "news_date": "2023-08-11 18:45:38",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended  30Th June, 2023",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30th June, 2023",
            "news_id": "19daaf55-1105-47c2-9646-aa11cf87b567",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33e95a36-ca7c-4bcd-b529-08fc784b39ac.pdf",
            "news_date": "2023-08-11 18:01:38",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the Earnings Call",
            "news_id": "f6b0983c-d5b0-4e83-b2ed-5c6e6a8b6afd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4199010-413e-4507-b52e-68304100feed.pdf",
            "news_date": "2023-05-25 11:42:54",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 of FY 2022-23 Earnings Call held on 22nd May, 2023 on the website of the Company.",
            "news_id": "4b7f195b-64b9-4dd2-9cd2-0b36be57f96b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=583ccc99-674e-4eed-862b-e7f3ffd35495.pdf",
            "news_date": "2023-05-22 15:08:34",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation - Q4 FY 22-23 & FY 22-23.",
            "news_id": "e8f3f4ba-7a40-4b05-b137-45b82ec88c09",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64d89a7f-11cc-401a-99d3-52141d884373.pdf",
            "news_date": "2023-05-19 20:36:53",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Year Ended March 31, 2023",
            "news_body": "The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 19, 2023, which commenced at 02.00 p.m. and concluded at 06.40 p.m., considered and approved the following:<BR> <BR> 1. Audited Financial Results for the quarter and year ended March 31, 2023. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com <BR> <BR> 2. Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2022-23 subject to the approval of the Shareholders at the ensuing Annual General Meeting.",
            "news_id": "4cccc6ff-5e4e-40b1-939a-8fba054a5990",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c395378e-d7d1-4206-9d4d-1318793dd88b.pdf",
            "news_date": "2023-05-19 19:00:00",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the Earnings Call",
            "news_id": "b8fc7268-d35b-4639-896b-502a770b6c9c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9a0f290-cf94-4692-8a1d-400da3e05b74.pdf",
            "news_date": "2023-02-15 17:54:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 of FY 2022-23 Earnings Call held on 13th February, 2023 on the website of the Company.",
            "news_id": "acb0466e-733e-46a1-81bf-b8287c750b65",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f6b7ec4-d890-4964-ae15-42b5d6062add.pdf",
            "news_date": "2023-02-13 13:06:44",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation Q3 FY23.",
            "news_id": "019c4fbd-cf69-4ae6-b997-0fb7e0f2cc59",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad7ff6c6-8655-4dc4-a261-c53a6314cf51.pdf",
            "news_date": "2023-02-10 20:14:08",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the<BR> Third Quarter and Nine Months ended December 31, 2022.<BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 7.25 p.m.<BR> The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith.<BR> These are also being made available on the website of the Company.",
            "news_id": "99181423-3b2e-4eab-913e-7551c045cd45",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66e798c3-956e-4c7f-9b1a-86d560dcc215.pdf",
            "news_date": "2023-02-10 19:47:01",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 30Th September, 2022",
            "news_body": "Disclosure of Related Party Transactions for the half year ended 30th September, 2022",
            "news_id": "fa5a9edc-6304-472b-85e6-ff8db8b74dc6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd0ea7d2-6298-4c5e-833c-aba49c3c9e39.pdf",
            "news_date": "2022-11-25 21:52:56",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 03rd November, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings call held on Monday, November 14, 2022 for the quarter and half year ended September 30, 2022 has been uploaded on the Company's website",
            "news_id": "26dea815-9e75-4a1b-89ec-7ff596493fdb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65080f5c-eedf-49ea-8e85-86fce45d513d.pdf",
            "news_date": "2022-11-18 16:17:11",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2022 which is scheduled today at 17:30 IST, in Mumbai.Kindly take the same on record and acknowledge receipt.",
            "news_id": "df9ede70-3b86-428f-9d5e-166db0bd213d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8dce3da7-7f5a-4e96-b106-8970e4a0c8f1.pdf",
            "news_date": "2022-11-17 17:19:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of Q2 of FY 2022-23 Earnings Call",
            "news_id": "3c11e6bd-7380-4140-a0e2-e54331422bd6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8da8ba86-6d75-47ae-8b30-e7e1ac9499d9.pdf",
            "news_date": "2022-11-14 22:25:19",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second<BR> Quarter and Half Year ended September 30, 2022.<BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.20 p.m.<BR> The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> These are also being made available on the website of the Company at www.glenmarkpharma.com",
            "news_id": "19876e8d-b473-4cd7-b364-502801cef650",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c213bac9-eced-4c2f-99e2-de5c3260f970.pdf",
            "news_date": "2022-11-11 18:47:29",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 01st August, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, August 12, 2022 for the quarter ended June 30, 2022 has been uploaded on the Company's website.",
            "news_id": "dd44a2a6-e4b3-43b2-bf2d-5179916ea2ef",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23e6cd1c-b83c-46c6-bfae-d333481e2332.pdf",
            "news_date": "2022-08-17 11:01:20",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results Standalone And Consolidated For The First Quarter Ended June 30, 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First<BR> Quarter ended June 30, 2022.<BR> The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.10 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release<BR> Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> These are also being made available on the website of the Company",
            "news_id": "f050a807-61c6-4ca8-8617-276b40b848ba",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0af2818f-d831-426b-9449-1abf28c25eb7.pdf",
            "news_date": "2022-08-10 18:39:26",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 31St March, 2022",
            "news_body": "Disclosure of Related Party Transactions for the half year ended 31st March, 2022",
            "news_id": "4bb9534c-3d9c-4670-86c1-732977cd05d6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0de130e4-b62b-4e83-bf55-77ef01d0da27.pdf",
            "news_date": "2022-06-10 18:12:46",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our letter dated 19th May, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015,the transcript of the Earnings call held on Monday, May 30, 2022 for the quarter and year ended March 31, 2022 has been uploaded on the Company's website.",
            "news_id": "a3de107e-4c70-4c61-a63f-1641be2f4cf1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c087f257-ede7-4807-8153-2594b1db9481.pdf",
            "news_date": "2022-06-03 17:37:20",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of Q4 & FY22 Earnings Call",
            "news_id": "58734a68-1de5-4ad0-ab6a-4ef0d5fda426",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45209f6f-4b2c-4972-81ea-7ddccb5c6a9e.pdf",
            "news_date": "2022-05-30 12:58:54",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Year Ended March 31, 2022",
            "news_body": "Audited Financial Results for the year ended March 31, 2022. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Investor Presentation, Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com<BR>",
            "news_id": "3587bd94-8ac0-4474-8695-dfc56bfc1d39",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9756ad4c-a893-4cdc-9315-5b43b500bbc4.pdf",
            "news_date": "2022-05-27 23:02:45",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2021",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the                        Third Quarter and Nine Months ended December 31, 2021.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 10.15 p.m.<BR>  <BR> The copy of the said results together with Press Release, Management Discussion & Analysis, Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR>",
            "news_id": "aa419cd6-62bd-4a60-b819-75453a72a029",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97854b39-1e67-449e-9644-c90583014762.pdf",
            "news_date": "2022-02-11 22:40:13",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2021",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2021.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.40 p.m.<BR>  <BR> The copy of the said results together with Management Discussion & Analysis, Press Release, Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> <BR> These are also being made available on the website of the Company at www.glenmarkpharma.com<BR> <BR> You are requested to take the same on record.<BR>",
            "news_id": "8082783b-d611-4d38-912e-6d58e0d9de31",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72f9262f-5b86-4fab-8639-43767096f2fa.pdf",
            "news_date": "2021-11-12 22:08:27",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended June 30, 2021",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First Quarter ended June 30, 2021.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.15 p.m.<BR>  <BR> The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith.<BR> <BR> These are also being made available on the website of the Company at www.glenmarkpharma.com<BR>",
            "news_id": "5def1a71-ed3f-47ff-947c-6a70a3ec5d73",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27fbba66-db64-4f74-b0f8-28eb4b453333.pdf",
            "news_date": "2021-08-13 21:42:22",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015",
            "news_body": "Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards for the period ended 31st March, 2021.",
            "news_id": "2c32cc11-d09e-469f-bc6e-6983644b110f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c66fe3a9-4292-4808-bb00-b3b68d4a234d.pdf",
            "news_date": "2021-06-25 20:13:17",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Year Ended March 31, 2021",
            "news_body": "Audited Financial Results for the year ended March 31, 2021. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Investor Presentation, Auditors Report and Declaration of unmodified opinion.<BR> Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2020 - 21 subject to the approval of the Shareholders at the ensuing Annual General Meeting.",
            "news_id": "30d23a20-0f5e-4e05-ade1-2d6a802b288e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2b03464-b23e-4e55-94a7-dc0a02aaabdf.pdf",
            "news_date": "2021-05-28 22:24:27",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "GLENMARK",
            "disp": "Glenmark Pharmaceuticals",
            "bse_code": 532296,
            "isin": "INE935A01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2020",
            "news_body": "Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2020.<BR> <BR> The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.20 p.m.<BR>  <BR> The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith.<BR> <BR> These are also being made available on the website of the Company at www.glenmarkpharma.com",
            "news_id": "a6344939-49e9-4cc5-83d8-f3fba7e4ca9a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55826d67-d9a0-4205-8a23-c4f47924ab52.pdf",
            "news_date": "2021-02-12 21:36:26",
            "seo": "glenmark-pharmaceuticals-ltd",
            "ltp": 2015.2,
            "ch": 57.200000000000045,
            "pch": 2.921348314606744,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 7406,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}